Genetics of Breast and Ovarian Cancer - National Cancer Institute

Table 7. Uptake of Risk-Reducing Salpingo-Oophorectomy (RRSO) and/or Gynecologic Screening

Study Citation Study Population RRSO Gynecological Screening Length of Follow-up Comments

United States

[172] Carriers (N = 132)^a BRCA1 BRCA1 Not provided Specific method(s) of gynecological screening not reported.

Carriers 33% Carriers 53%

Noncarriers (N = 410)^a BRCA2 BRCA2

Carriers 41% Carriers 50%

Noncarriers 8% Noncarriers 76%

[173] Carriers (N = 79)^a Carriers 27% CA 125 12 mo

Carriers 43%

Noncarriers 9%

Noncarriers (N = 44)^a Uninformative 27%

TVUS

Uninformative (N = 166)^a Carriers 40%

Noncarriers 21%

Uninformative 29%

[171] Carriers (N = 26)^a Carriers 46% CA 125 24 mo

Carriers 37%

Noncarriers 5%

Noncarriers (N = 66)^a Declined test 8%

TVUS

Declined testing (N = 12)^a Carriers 11%

Noncarriers 2%

Declined test 8%

[170] Carriers (N = 179)^{a, b} Carriers 50.3% CA 125 Mean 24.8 mo; range 1.6–66.0 mo Women undergoing RRSO were older and more likely to have a personal history of breast cancer.

Carriers 67.6%

TVUS

Carriers 72.9%

[124] Carriers (N = 39)^a Carriers 13% CA 125 12 mo

Carriers 21%

TVUS

Carriers 15%

International

[162] Carriers (N = 70)^a Carriers 29% CA 125 3 y

Carriers 0%

TVUS

Carriers 67%

[163] Carriers aged ≥35 years (N = 16)^a Carriers aged ≥35 years 75% CA 125 12 mo Women undergoing RRSO were older and had higher ovarian cancer risk perception.

Not evaluated

Carriers aged <35 years (N = 12)^a Carriers aged <35 years 8% TVUS

Carriers aged ≥35 years 100%

Carriers aged < 35 years 30%

[164] Carriers (N = 26)^a Carriers 50% NA 12 mo

Noncarriers (N = 37)^a

[165] Carriers (N = 45)^b Carriers 64% Carriers 36% Median 24 mo; range 11–61 mo 83% of RRSOs were performed within 9 months of receiving test results.

Specific method(s) of gynecological screening not reported.

[174] Carriers (N = 160)^{a, b} Carriers 64% Carriers 26% 12 mo Women undergoing RRSO had lower education levels, viewed ovarian cancer as incurable and believed strongly in the benefits of RRSO.

Specific method(s) of gynecological screening not reported.

[167] Carriers (N = 2,677)^a Carriers 57% NA 3.9 y; range 1.5–10.3 y Large differences in uptake of risk management options by country.

[168] Carriers (N = 537)^c Carriers 55% NA Minimum 6 mo; median 36 mo RRSO greatest in parous women aged >40 years.

^aSelf-report as data source.

^bMedical records as data source.

^cData source not specified.

TVUS = transvaginal ultrasound.

Bibliografía

Lerman C, Hughes C, Croyle RT, et al.: Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31 (1): 75-80, 2000. [PUBMED Abstract]
Phillips KA, Jenkins MA, Lindeman GJ, et al.: Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clin Genet 70 (3): 198-206, 2006. [PUBMED Abstract]
Claes E, Evers-Kiebooms G, Decruyenaere M, et al.: Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behav Med 31 (3): 93-105, 2005. [PUBMED Abstract]
Lodder LN, Frets PG, Trijsburg RW, et al.: One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 73 (2): 97-112, 2002. [PUBMED Abstract]
Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al.: Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355 (9220): 2015-20, 2000. [PUBMED Abstract]
Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al.: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122 (9): 2017-22, 2008. [PUBMED Abstract]
Friebel TM, Domchek SM, Neuhausen SL, et al.: Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer 7 (11): 875-82, 2007. [PUBMED Abstract]
Scheuer L, Kauff N, Robson M, et al.: Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20 (5): 1260-8, 2002. [PUBMED Abstract]
Botkin JR, Smith KR, Croyle RT, et al.: Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118 (3): 201-9, 2003. [PUBMED Abstract]
Uyei A, Peterson SK, Erlichman J, et al.: Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 107 (12): 2745-51, 2006. [PUBMED Abstract]
Schwartz MD, Kaufman E, Peshkin BN, et al.: Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 21 (21): 4034-41, 2003. [PUBMED Abstract]
Madalinska JB, van Beurden M, Bleiker EM, et al.: Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J Clin Oncol 25 (3): 301-7, 2007. [PUBMED Abstract]